Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA-2)

6. november 2026 oppdatert av: Regeneron Pharmaceuticals

Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva

This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years.

The aim of the study is to see how safe, tolerable, and effective the study drug is.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

18

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 18 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. For USA participants, age criteria are 4 to < 18 years old, at the time of the administration of the first dose of study intervention. Non-USA participants age criteria are 2 to < 18 years old

  2. Must have a confirmation of FOP diagnosis, as described in the protocol

  3. At the time of enrollment, participants must weight:

    1. Cohort 1: more than 30 kg (or 66.1 pounds)
    2. Cohort 2: more than 30 kg (or 66.1 pounds)
    3. Cohort 3: less than or equal to 30 kg (or 66.1 pounds)

Key Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS) score > 19 at the time of screening
  2. Participant has significant concomitant illness or history of significant illness, as described in the protocol
  3. Previous history or diagnosis of cancer
  4. Ongoing significant viral or bacterial illness, within 2 weeks of the first study drug administration
  5. History of severe respiratory compromise requiring oxygen, respiratory support
  6. Known history of cerebral vascular malformation
  7. Participants with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
  8. Participants with a known pre-existing medical history of a bleeding diathesis, as described in the protocol
  9. Participants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cohort 1: Adolescents

Participants aged 12 - 18 years old

Administered per the protocol

Andre navn:
  • REGN2477
  • PASATRU™
Eksperimentell: Cohort 2: Children

Children who are 4 to 12 years old (for non-US sites only 2 to 12 years old)

Administered per the protocol

Andre navn:
  • REGN2477
  • PASATRU™
Eksperimentell: Cohort 3: Children and Adolescents

Participants and Children aged 4 to 18 years old (for non-US sites only 2 to 18 years old)

Administered per the protocol

Andre navn:
  • REGN2477
  • PASATRU™

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Severity of TEAEs
Tidsramme: Baseline to week 56
Baseline to week 56
Concentrations of functional garetosmab in serum
Tidsramme: Through week 56
Through week 56
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
Tidsramme: Baseline to week 56
Baseline to week 56

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of new HO lesions
Tidsramme: At week 28 and week 56
At week 28 and week 56
Occurrence of new HO lesions
Tidsramme: At week 28 and week 56
At week 28 and week 56
Number of clinician-assessed flare-ups
Tidsramme: Through week 28 and week 56
Through week 28 and week 56
Occurrence of clinician-assessed flare-ups
Tidsramme: Through week 28 and week 56
Through week 28 and week 56
Characteristics of menstrual cycles for female participants who reached menarche
Tidsramme: Over 28 weeks and 56 weeks
Over 28 weeks and 56 weeks
Concentrations of total activin A in serum
Tidsramme: Through week 56
Through week 56
Occurence of Anti-Drug Antibody (ADA) to garetosmab
Tidsramme: Through week 56
Through week 56
Magnitude of ADA to garetosmab
Tidsramme: Through week 56
Through week 56
Change from baseline in hearing function as assessed by audiometry
Tidsramme: At week 28 and week 56
At week 28 and week 56
Total volume of new Heterotopic Ossification (HO) lesions
Tidsramme: At week 28 and week 56
At week 28 and week 56
Change from baseline in total volume of HO lesions
Tidsramme: At week 28 and week 56
At week 28 and week 56
Change from baseline in Tanner puberty scale
Tidsramme: At week 28 and week 56

Tanner puberty scale or stages: Staging of sexual development is graded on a 5-point ordinal scale ranging from 1 (prepubertal) to 5 (adultlike) for female breast development, male external genitals, and pubic hair

At week 28 and week 56
Height-for-age Z-Scores according to the World Health Organization (WHO) Growth Reference Data for Children
Tidsramme: Through week 56

Participants 5-19 years of age Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.

Through week 56
Change from baseline in knee height
Tidsramme: At week 28 and week 56
At week 28 and week 56
Change from baseline in Pediatric Quality of Life inventory (PedsQL) scores
Tidsramme: At week 28 and week 56

Age-appropriate PedsQL Generic Core Scales will be used to measure HRQoL in children and adolescents. Response options include 5-point Likert scale (or 3-point Likert scale for the young children self-report) for each item asking about experience within the past week. Global scores are transformed to a 0 to 100 scale with higher scores indicating better quality of life.

At week 28 and week 56
Acceptability or tolerability assessment via exit interview
Tidsramme: Up to week 52

Each interview will be conducted by trained external interviewers following a semi-structured interview guide of questions for the participants about their overall experience in the trial.

Up to week 52

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

2. februar 2027

Primær fullføring (Antatt)

8. juli 2030

Studiet fullført (Antatt)

8. juli 2030

Datoer for studieregistrering

Først innsendt

22. april 2026

Først innsendt som oppfylte QC-kriteriene

22. april 2026

Først lagt ut (Faktiske)

30. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD-delingstidsramme

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Tilgangskriterier for IPD-deling

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere